Receipt of Notice from Biogen

On January 13, 2023, Forward Pharma A/S (the "Company") received notice from the two wholly owned subsidiaries of Biogen Inc. ("Biogen") party to the Settlement and License Agreement with the Company, dated January 17, 2017 (the "License Agreement"), of their exercise of the option to purchase the intellectual property outside of the United States associated with the Company (the "Designated Countries IP") pursuant to the License Agreement. The Company and Biogen have consummated the assignment of the Designated Countries IP to Biogen upon the execution of assignment agreements and the payment of a nominal amount by Biogen to FWP IP ApS, and Biogen has assumed ownership and responsibility for the assigned Designated Countries IP.

Attachments

Disclaimer

Forward Pharma A/S published this content on 13 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 January 2023 21:49:01 UTC.